Tendinous disorders attributed to statins: A study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature

Arthritis Care and Research

Volumn 59, Issue 3, 2008, Pages 367-372

  Marie, Isabelle ^a   Delafenêtre, Hélène ^a   Massy, Nathalie ^a   Thuillez, Christian ^a   Noblet, Catherine ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; ISOTRETINOIN; METFORMIN; PRAVASTATIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROSUVASTATIN; SIMVASTATIN; STEROID;

ACHILLES TENDINITIS; AGED; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RECURRENT DISEASE; RETROSPECTIVE STUDY; TENDINITIS; TENDON RUPTURE;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; FRANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PREVALENCE; REGISTRIES; RETROSPECTIVE STUDIES; TENDINOPATHY;

EID: 40849104909     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23309     Document Type: Article

References (45)

1. Albert MA, Danielson E, Rifai N, Ridker PM, and the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
2. Arntz HR, Agrawal R, Wunderlich W, Schnitzer L, Stern R, Fischer F, et al. Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol 2000;86:1293-8.
3. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus "usual" care in secondary coronary heart disease prevention: the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-8.
4. Bertrand ME, McFadden EP, Fruchart JC, Van Belle E, Commeau P, Grollier G, et al, for the PREDICT Trial Investigators. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty: prevention of restenosis by Elisor after transplantation coronary angioplasty. J Am Coll Cardiol 1997;30:863-9.
5. Bestehorn HP, Rensing UF, Roskamm H, Betz P, Benesch L, Shcemeitat K, et al. The effect of simvastatin on progression of coronary artery disease: the Multicenter Coronary Intervention Study (CIS). Eur Heart J 1997;18:226-34.
6. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
7. Crouse JR 3rd, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) [published erratum appears in Am J Cardiol 1995;75:862]. Am J Cardiol 1995;75:455-9.
8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al, for the Air Force/Texas Coronary Atherosclerosis Prevention Study. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
9. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ 3rd, Jones PH, West MS, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997;805:278-86.
10. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.
11. Marschner IC, Colquhoun D, Simes RJ, Glasziou P, Harris P, Singh BB, et al, for the LIPID Study Investigators. Long-term risk stratification for survivors of acute coronary syndromes: results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. J Am Coll Cardiol 2001;38:56-63.
12. McCormick LS, Black DM, Waters D, Brown WV, Pitt B. Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT). Am J Cardiol 1997;80:1130-3.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
14. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995;26:1133-9.
15. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous vein coronary-artery bypass grafts [published erratum appears in N Engl J Med 1997;337:1859]. N Engl J Med 1997;336:153-62.
16. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
17. Sacks FM, Pfeffer MA, Moye LA, Brown LE, Hamm P, Cole TG, et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE). Am J Cardiol 1991;68:1436-46.
18. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
19. Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia: Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002;39:610-6.
20. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al, and the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized control trial. JAMA 2001;285:1711-8.
21. Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the Fluvastatin Angiographic Restenosis (FLARE) trial. Eur Heart J 1999;20:58-69.
22. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al, and the PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
23. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
24. Van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschkle AV, for the REGRESS Study Group. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation 1996;94:1503-5.
25. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-68.
26. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997;96:1398-402.
27. Andrejak M, Gras V, Massy ZA, Caron J. Adverse effects of stains. Therapie 2003;58:77-83. In French.
28. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109(23 Suppl 1):III50-7.
29. Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med 2002;137:617-8.
30. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-5.
31. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90.
32. Tsivgoulis G, Spengos K, Karandreas N, Panas M, Kladi A, Manta P. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med 2006;166:1519-24.
33. Chazerain P, Hayem G, Hamza S, Best C, Adda C, Ziza JM. Trois cas de tendinopathie induite par une statine [abstract]. Rev Med Interne 2000;21:268.
34. Chazerain P, Hayem G, Hamza S, Best C, Ziza JM. Four cases of tendinopathy in patients on statin therapy. Rev Rhum 2001;68:865-9. In French.
35. Falip S, Battlo M, Peyriere H, Blayac JP, Hillaire-Buys D. Statin induced tendinopathies: analysis of 37 cases in the French Pharmacovigilance database [abstract]. Fundam Clin Pharmacol 2005;19:231.
36. Rodor F, Beurois G, Prost N, Tichadou L, N'Guyen N, Benjelloun R, et al. Statin's tendonitis [abstract]. Therapie 2000;55:422. In French.
37. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003;36:1404-10.
38. Van der Linden PD, van de Lei J, Nab HW, Knol A, Stricker BH. Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol 1999;48:433-7.
39. Van der Linden PD, van Puijenbroek EP, Feenstra J, in 't Veld BA, Sturkenboom MC, Herings RM, et al. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Rheum 2001;45:235-9.
40. Royer RJ, Pierfitte C, Netter P. Features of tendon disorders with fluoroquinolones [letter]. Therapie 1994;49:75-6.
41. Van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Strieker BH. Fluoroquinolones and increased risk of Achilles tendon disorders: case-control study. Br Med J 2002;324:1306-7.
42. Navaneethan SD, Shrivastava R. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 2004;4:CD004289.
43. Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet PC, Bertin P. et al. Fluoroquinolone induced tendinopathy: report of 6 cases. J Rheumatol 1996;23:516-20.
44. Saint F, Salomon L, Cicco A, de la Taille A, Chopin D, Abbou CC. Tendinopathy associated with fluoroquinolones: individuals at risk, incriminated physiopathologie mechanisms, therapeutic management. Prog Urol 2001;11:1331-4. In French.
45. Simonin MA, Gegout-Pottie P, Minn A, Gillet P, Netter P, Terlain A. Pefloxacin-induced Achilles tendon toxicity in rodents: biochemical changes in proteoglycan synthesis and oxidative damage to collagen. Antimicrob Agents Chemother 2000;44:867-72.